Emergent BioSolutions To Acquire Protein Sciences’ Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), And Related Novel Platform Technology

Emergent BioSolutions Inc. (NYSE:EBS) and Protein Sciences Corporation (PSC), based in Meriden, Connecticut, announced that the two companies have entered into an asset purchase agreement under which Emergent will acquire PSC’s ongoing operations, including FluBlok, a Phase III recombinant influenza vaccine candidate, and certain other assets. This agreement achieves a key component of Emergent’s stated strategy for growth through acquisition of late-stage product candidates.

More: continued here

Filed under: Flu / SARS on June 1st, 2008